Abstract. Ameloblastic carcinoma, secondary type, is an extremely rare odontogenic malignant tumor. The present study reports the case of a 58-year-old male with ameloblastic carcinoma that extended into the intracranial space close to the internal carotid artery. Surgical excision was performed, as headaches were being caused via compression by the mass. Small remnants of the tumor remained surrounding the internal carotid artery following surgical resection. Although the remnant tissue was not detected on magnetic resonance imaging or 18F‑fluorodeoxyglucose (FDG)‑positron emission tomography (PET), it was clearly visualized on 11C‑methionine PET in the early post‑operative follow‑up period. No neurological deficits were exhibited during the follow-up period, and 11C‑methionine PET was able to detect the remnant lesion distribution in the intracranial space. The current study presents a rare case of ameloblastic carcinoma that extended into the intracranial space. In addition, several diagnostic imaging tools were compared in order to determine the most suitable imaging modality. At present, the patient is continuing a therapeutic course of radiation and evident mass reduction has been observed. However, the therapeutic effects are currently under consideration. To the best of our knowledge, this is the first study on the effectiveness of using 11C‑methionine PET for detecting ameloblastic carcinoma with intracranial extension.

Introduction

Ameloblastic carcinoma, peripheral secondary type, is a rare odontogenic carcinoma (1), and few cases of the intracranial extension of these tumors have been reported. Ameloblastic carcinoma is defined as a rare malignant odontogenic tumor that retains the histological features of ameloblastoma and also exhibits cytological features of malignancy (1-5). 11C‑methionine positron emission tomography (PET) is the most common method used to detect intracranial malignancies with high resolution, as 11C‑methionine is preferentially absorbed in tissue with highly active amino acid and protein synthesis. Protein synthesis is initiated at the first methionine amino acid and the level of 11C‑methionine uptake indicates the level of protein synthesis. As the normal brain tissue has low levels of protein synthesis activity, intracranial malignant lesions usually uptake much higher levels of 11C-methionine. Predominantly, 11C-methionine PET is applied to detect malignant lesions in the head and neck region and has never been used for the detection of ameloblastic carcinoma, due to the rarity of the tumor (6-8). The current study presents a rare case of maxillary ameloblastic carcinoma, peripheral secondary type, extending into the right middle cranial fossa. In addition, the value of 11C-methionine PET is discussed with regard to detecting ameloblastic carcinoma. The patient provided written informed consent.

Case report

A 58-year-old male was admitted to the Hokuto Hospital (Hokkaido, Japan) with a moderate headache and dizziness. The patient had a normal level of consciousness. No evident central nervous system disorders were observed. The patient had a history of ameloblastoma, which had been treated 12 years prior to admission. The post-operative follow-up for this occurrence had been discontinued by the Obihiro-Kosei General Hospital (Obihiro, Japan).

Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a mass lesion in the right infratemporal fossa, middle cranial space and upper maxilla, with a wide-range bone defect in the right middle skull base (Fig. 1 and 2). A histopathological specimen was obtained from the tumor in the oral cavity. Hematoxylin and eosin (HE) staining demonstrated marked atypia, high cellularity, hyperkeratosis and necrosis surrounded by the typical ameloblastoma histology (Fig. 3). MIB-1 staining showed 25% positive cells in the lesion (Fig. 3). These findings indicated a diagnosis of ameloblastic carcinoma.
For contrast agents, 185 MBq 18F-fluorodeoxyglucose and 370 MBq 11C-methionine (10 mCi) were injected intravenously as bolus injections. PET revealed a high level of accumulation of 18F-fluorodeoxyglucose (FDG) and 11C-methionine in the mass (Fig. 4). No evident lesions were detected, except for the brain mass, on enhanced whole-body MRI or PET.

A surgical resection of the tumor was performed. Almost all the tumor components were removed, except for a small amount of remnant tissue around the right internal carotid artery. During the early post-operative follow-up period, although neither FDG-PET nor enhanced MRI could visualize the residual tissue, 11C-methionine PET was able to detect the tumor remnant (Fig. 5). At present, the patient is continuing a therapeutic course of radiation and evident mass reduction has been observed. However, the therapeutic effects are currently under consideration.

Discussion

According to the 2005 histological classification by the World Health Organization (WHO), ameloblastic carcinoma is classified into the primary type, the intraosseous secondary type and the peripheral secondary type (1,2). Whereas primary-type ameloblastic carcinoma develops de novo, secondary-type ameloblastic carcinoma is derived from the malignant transformation of ameloblastoma due to repeated inflammatory stimulation (3). Ameloblastic carcinoma exhibits cytological atypia, with or without metastasis (4,5). In the present study, due
Figure 3. Immunohistochemical study. Hematoxylin and eosin staining results showing (A) a level of high cellularity (magnification, x200), with (B) hyperkeratosis (magnification, x100) and (C) necrosis (magnification, x200). (D) MIB-1 staining (magnification, x200). The proportion of MIB-1-positive cells was ~25%.

Figure 4. Positron emission tomography scan prior to surgery showing a high accumulation of (A) $^{11}$C-methionine and (B) 5-fluorodeoxyglucose in the mass lesion.

Figure 5. Post-operative examination. (A, B) Enhanced MRI and (D) FDG-PET were unable to visualize the remnant tissue. (C) $^{11}$C-methionine-PET clearly revealed the remnant tissue of the ameloblastic carcinoma around the right internal carotid artery.
to the patient’s past history of ameloblastoma and the findings of histopathological malignancy, a diagnosis of ameloblastic carcinoma, peripheral secondary type, was made. Furthermore, the ameloblastic carcinoma had extended into the intracranial space. Although odontogenic tumors typically arise from oral cavity tissues, one study in the English literature has indicated that these lesions can grow in the head and neck region (9). Furthermore, a small number of studies have also reported the intracranial extension of ameloblastoma (10‑14), while a few others have presented cases of ameloblastic carcinoma with extension into the intracranial space or cranial bone (15‑17).

Enhanced CT or MRI and/or FDG‑PET are generally used to detect the regrowth or metastasis of tumors. In contrast, X‑ray, plain CT and enhanced CT are usually applied in cases of malignant ameloblastoma or ameloblastic carcinoma. To the best of our knowledge, the extension of these tumors into the intracranial space is generally detected using plain or enhanced CT (10‑14,16). MRI is also useful for detecting the intracranial extension of ameloblastic carcinoma (16). Furthermore, FDG‑PET is often applied to assess systemic metastasis (17,18) and skull bone metastasis (17) of ameloblastic carcinoma. However, no previous studies have reported the value of methionine PET for treating ameloblastic carcinoma.

Generally, intracranial malignant lesions are identified on enhanced CT or MRI. Although whole-body FDG‑PET is useful for detecting the systemic distribution of malignant lesions (19‑22), it is difficult to evaluate small intracranial lesions by this method, as normal brain tissues also exhibit the uptake of FDG to a certain extent (23,24). As protein synthesis is upregulated in tumor cells compared with that observed in the central nervous system, methionine PET is useful for visualizing the clear border of intracranial malignant lesions in cases of glioma (25). In addition, a positive association has been reported between the efficiency of methionine accumulation and the MIB‑1 index, an indicator of the proliferation of malignancy, in the setting of rectal cancer metastasis (26). In previous studies, FDG‑PET has been described as a diagnostic tool for detecting ameloblastic carcinoma (17‑19). The present study confirmed that methionine PET is superior to FDG‑PET in detecting intracranial ameloblastic carcinoma, with remarkable sensitivity. In the present case, only methionine PET was able to detect the extremely small amount of remnant tissue of the post‑operative ameloblastic carcinoma surrounding the internal carotid artery (Fig. 5C and D). To the best of our knowledge, there have been no previous studies regarding the effectiveness of methionine PET in diagnosing ameloblastic carcinoma. In this case, the accumulation of methionine in the ameloblastic carcinoma lesion was clearly observed on a PET scan (Fig. 4A and 5C). These findings indicate that methionine PET is a more useful diagnostic tool than FDG‑PET for detecting intracranial ameloblastic carcinoma.

References

1. Yoshioka Y, Toratani S, Ogawa I and Okamoto T: Ameloblastic carcinoma, secondary type, of the mandible: a case report. J Oral Maxillofac Surg 71: e58‑e62, 2013.

2. Barnes L, Eveson J, Reichat P and Sidransky D: World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. IARC Press, Lyon, France, pp286‑291, 2005.

3. Karakida K, Aoki T, Sakamoto H, et al: Ameloblastic carcinoma, secondary type: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110: e33‑e37, 2010.

4. Francas DC, Moreira MM, De Aguiar SM, De Carvalho AA and Goiato MC: Ameloblastic carcinoma of the maxilla: A case report. Oncol Lett 4: 1297‑1300, 2012.

5. Madan M, Singh J, Arora R and Bansal M: Ameloblastic carcinoma: A case report and literature review. Int J Appl Basic Med Res 1: 54‑56, 2011.

6. Glaudemans AW, Enting RH, Heesters MA, et al: Value of 11C‑methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging 40: 615‑635, 2013.

7. Crippa F, Alessi A and Serafini GL: PET with radiolabeled aminoacid. Q J Nucl Med Mol Imaging 56: 151‑162, 2012.

8. Caylor B and Halldin C: New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging 56: 173‑190, 2012.

9. Temporale H, Zatoński T, Roszkowska A and Kręcicki T: Ameloblastoma of the nasal septum origin: a case report. Case Rep Otolaryngol: Sep 21, 2013 (Epub ahead of print).

10. Takeuchi S, Kobayashi K, Minakawa A, Azumi T and Fukushima M: Metastatic ameloblastoma of the skull. Surg Neurol 15: 182‑185, 1981.

11. Azumi T, Nakajima T, Takeuchi S, Fukushima M and Ishiki T: Malignant ameloblastoma with metastasis to the skull: report of a case. J Oral Surg 49: 623‑627, 1981.

12. Sato K, Sudo S, Fukuya S and Sakuma H: Maxillary ameloblastoma with intracranial invasion - case report. Neurol Med Chir (Tokyo) 34: 704‑707, 1994.

13. Hayashi N, Iwata J, Masaoka N, Ueno H, Otsubo Y and Moriki T: Ameloblastoma of the mandible metastasizing to the orbit with malignant transformation. A histopathological and immunohistochemical study. Virchows Arch 430: 501‑507, 1997.

14. Leibovitch I, Schwarcz RM, Modjtabadi S, Selva D and Goldberg RA: Orbital invasion by recurrent maxillary ameloblastoma. Ophthalmology 113: 1227‑1230, 2006.

15. Benlyazid A, Lacroix‑Triki M, Aziza R, Gomez‑Brouchet A, Guichard M and Sarini J: Ameloblastic carcinoma of the maxilla: case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104: e17‑e24, 2007.

16. Ozlugedik S, Ozcan M, Basturk O, et al: Ameloblastic carcinoma arising from anterior skull base. Skull Base 15: 269‑273, 2005.

17. Devenney‑Cakir B, Dunbee F, Subramaniam R, et al: Ameloblastic carcinoma of the mandible with metastasis to the skull and lung: advanced imaging appearance including computed tomography, magnetic resonance imaging and positron emission tomography. Dentomaxillofacial Radiol 39: 449‑453, 2010.

18. Matsuizaki H, Katase N, Hara M, et al: Ameloblastic carcinoma: a case report with radiological features of computed tomography and magnetic resonance imaging and positron emission tomography. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112: e40‑e47, 2011.

19. Davis KR, New PF, Solis OJ and Roberson GH: A review of the findings on computed cranial tomography following intravenous contrast media. Rev Interam Radiol 2: 15‑18, 1977.

20. Graif M and Steiner RE: Contrast‑enhanced magnetic resonance imaging of tumors of the central nervous system: a clinical review. Br J Radiol 59: 865‑873, 1986.

21. Wilms G, Marchal G, DeMaerel PH, Van Hecke P and Baert AL: Gadolinium‑enhanced MRI of intracranial lesions. A review of indications and results. Clin Imaging 15: 153‑165, 1991.

22. Dillon WP: Imaging of central nervous system tumors. Curr Opin Radiol 3: 46‑50, 1991.

23. Olivero WC, Dulebohn SC and Lister JR: The use of PET in imaging head and neck tumors. Clin Imaging 13: 239‑253, 1989.

24. Chen W: Clinical applications of PET in brain tumors. J Nucl Med 48: 1468‑1481, 2007.

25. Van Laere K, Ceyssens S, Van Calenbergh F, et al: Direct comparison of 18F‑FDG and 11C‑methionine PET in suspected recurrence of glioma: sensitivity, interobserver variability and prognostic value. Eur J Nucl Med Mol Imaging 32: 39‑51, 2005.

26. Koizumi M, Saga T, Yoshikawa K, et al: 11C‑methionine‑PET for evaluation of carbon ion radiotherapy in patients with pelvic recurrence of rectal cancer. Mol Imaging Biol 10: 374‑380, 2008.